Low risk of viral infection after administration of vapor‐heated factor VII concentrate or factor IX complex in first‐time recipients of blood components. International Factor Safety Study Group

Amy D. Shapiro(Apple (Israel)), K. Schimpf(Stiftung Rehabilitation Heidelberg (Germany)), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Georges‐Étienne Rivard(Centre Hospitalier Universitaire Sainte-Justine), K. Anderle(Ospedale L. Bonomo), Margaret W. Hilgartner(New York Academy of Medicine), M. Kunschak(Ospedale L. Bonomo), Takaya Abe(Ospedale L. Bonomo), F E Preston(Royal Hallamshire Hospital)
Transfusion
March 1, 1995
10.1046/j.1537-2995.1995.35395184275.x
Cited by 19

Related Papers

HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection
|Science|2004|1.2k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
Geographic Distribution of the 20210 G to A Prothrombin Variant
|Thrombosis and Haemostasis|1998|702